FDA Accepts Supplement for Abreva (Docosanol) by Haleon
The FDA has accepted a supplemental application for Abreva (docosanol) submitted by Haleon.
Therapeutic Area
Therapeutic area intelligence for Cold Sores with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.